J&J to appeal Razadyne patent ruling - MarketWatch News , chart , profile , more said early Thursday that it intends to appeal a ruling handed down by a Delaware District Court that declared the drugmaker's patent for the Alzheimer's disease drug Razadyne invalid. The ruling allows for the introduction of generic formulations of Razadyne before the patent's expiration date of December 2008. J&J intitiated the litigation in 2005 in an effort to prevent generic launches of the product by Barr Laboratories Intraday data provided by Interactive Data Real Time Services, a division of Interactive Data Corp. and subject to terms of use. Historical and current end-of-day data provided by Interactive Data Pricing and Reference Data. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones Indexes(SM) from Dow Jones Company, Inc. SEHK intraday data is provided by Comstock and is at least 60-minutes delayed. All quotes are in local exchange time. Real-time last sale data provided by NASDAQ.
